Anybody that tries to make a living on CTIX by waiting for the "Public Offering sell off" is going to be very disappointed - IMO.
And I am actually "pleased" with the S-3. I have experience with corporate finance and business negotiations. I was concerned that while our current financing was enough to sustain the company's current business plan, there was not much of a safety net. It also appears to me that we might have a need for additional trials beyond those currently scheduled and funded. But the main issue was the need to be strong financially for negotiating purposes. The value of negotiating from a position of strength cannot be overstated.
I've made a living hunting for shelf filings and waiting for the Public Offering sell off...no one is ever "pleased" to see a shelf filing. - starbuxsux
I follow your thinking SB. Not expecting them to use it right away and if they do dip into it, it would be in chunks IMO,. Possibly to put one of the other defensin-mimetic compounds into play. CTIX-1278 comes to mind. They won't want to burn through all the cash even with a portion still available with aspire. We've also seen shelf registrations go untouched and get cancelled down the road. We could play the "if" game with K, B or P alleviating the need completely.